Loading clinical trials...
Loading clinical trials...
Phase III Randomized, Placebo Controlled, Trial of Docetaxel Versus Docetaxel Plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions
Interventions
docetaxel
placebo
+1 more
Locations
1
United States
Eastern Cooperative Oncology Group
Boston, Massachusetts, United States
Start Date
August 1, 2004
Primary Completion Date
May 1, 2009
Completion Date
August 1, 2012
Last Updated
May 6, 2015
NCT05980000
NCT02358031
NCT03691714
NCT04969861
Lead Sponsor
National Cancer Institute (NCI)
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions